BBVA USA’s Coherus Oncology CHRS Stock Holding History

BBVA USA’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$57K	Buy	3,564 +2,948	+479%	+$43.2K	﹤0.01%	630
2021 Q2	$9K	Buy	+616	New	+$8.72K	﹤0.01%	869

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

BBVA USA's CHRS Position: Q3 2021 in Review

BBVA USA increased its Coherus Oncology (CHRS) stake by 479% in Q3 2021, buying an estimated $43.2K and bringing the position to 3,564 shares worth $57K. The position accounts for ﹤0.01% of the portfolio, ranked #630.

BBVA USA first reported a position in CHRS in Q2 2021 and has held it in 2 quarters since. 187 funds tracked by Wall St. Rank hold CHRS as of Q3 2021.

BBVA USA held 3,564 shares of Coherus Oncology worth $57K as of Q3 2021.
BBVA USA bought 2,948 Coherus Oncology shares in Q3 2021, an estimated $43.2K.
Coherus Oncology made up ﹤0.01% of BBVA USA's portfolio in Q3 2021, its #630 holding.
BBVA USA first reported a position in Coherus Oncology in Q2 2021 and has held it in 2 quarters since.
187 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2021.

Based on BBVA USA's 13F filing for Q3 2021, filed 4 Nov 2021.